PPARA and hyperlipidemia: Fibrates including gemfibrozil, bezafibrate and fenofibrate are synthetic PPARα agonists that decrease plasma TG levels and increase HDL-cholesterol levels in patients with hyperlipidemia and Type 2 diabetes, thereby preventing coronary heart disease and stroke [3,4,5,6,7].